This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (69)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Social Bookmarking   What's this?

Geelong Osteoporosis Study

Julie A. Pasco, PhD; Mark A. Kotowicz, MBBS, FRACP; Margaret J. Henry, PhD; Kerrie M. Sanders, MNutr, PhD; Geoffrey C. Nicholson, MBBS, PhD, FRACP, FRCP

Arch Intern Med. 2002;162:537-540.

Background  Recent data suggest that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) decrease fracture risk and increase bone mineral density (BMD).

Methods  This cross-sectional study is set in southeastern Australia. We evaluated the association between statin use, fracture risk, and BMD in 1375 women (573 with incident fractures and 802 without incident fracture, all drawn from the same community). Fractures were identified radiologically. Medication use and lifestyle factors were documented by questionnaire.

Results  Unadjusted odds ratio for fracture associated with statin use was 0.40 (95% confidence interval [CI], 0.23-0.71). Adjusting for BMD at the femoral neck, spine, and whole body increased the odds ratio to 0.45 (95% CI, 0.25-0.80), 0.42 (95% CI, 0.24-0.75), and 0.43 (95% CI, 0.24-0.78), respectively. Adjusting for age, weight, concurrent medications, and lifestyle factors had no substantial effect on the odds ratio for fracture. Statin use was associated with a 3% greater adjusted BMD at the femoral neck (P = .08), and BMD tended to be greater at the spine and whole body but did not achieve statistical significance.

Conclusion  The substantial 60% reduction in fracture risk associated with statin use is greater than would be expected from increases in BMD alone.

From the Department of Clinical and Biomedical Sciences–Barwon Health, The University of Melbourne, Geelong Hospital, Geelong, Australia.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Archives of Internal Medicine Reader's Choice: Continuing Medical Education
Arch Intern Med. 2002;162(5):615.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Effects of Atorvastatin on Bone in Postmenopausal Women with Dyslipidemia: A Double-Blind, Placebo-Controlled, Dose-Ranging Trial
Bone et al.
J. Clin. Endocrinol. Metab. 2007;92:4671-4677.
ABSTRACT | FULL TEXT  

Determinants of the Differences in LDL-Cholesterol After Initiation of Statin Treatment
Caspard et al.
The Annals of Pharmacotherapy 2006;40:21-26.
ABSTRACT | FULL TEXT  

Statin Use, Clinical Fracture, and Bone Density in Postmenopausal Women: Results from the Women's Health Initiative Observational Study
LaCroix et al.
ANN INTERN MED 2003;139:97-104.
ABSTRACT | FULL TEXT  

Statin Use Is Associated with Improved Function and Survival of Lung Allografts
Johnson et al.
Am. J. Respir. Crit. Care Med. 2003;167:1271-1278.
ABSTRACT | FULL TEXT  

Tackling ischaemic heart disease in rheumatoid arthritis
Kitas and Erb
Rheumatology (Oxford) 2003;42:607-613.
FULL TEXT  

Falls and 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors
Pasco et al.
Arch Intern Med 2002;162:2381-2381.
FULL TEXT  

Statin Use and Fracture Risk
Seeger et al.
Arch Intern Med 2002;162:2379-2380.
FULL TEXT